Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues
Targeted antitumour therapy has revolutionized the treatment of several types of tumours. Among the validated targets, phosphatidylinositol-3 kinase (PI3K) deserves to be highlighted. Several PI3K inhibitors have been developed for the treatment of cancer, including gedatolisib (<b>4</b>...
Main Authors: | Caroline Marques Xavier Costa, Cristiane Aparecida-Silva, Luis Eduardo Reina Gamba, Thalita Neves de Melo, Gisele Barbosa, Manoel Oliveira de Moraes Junior, Victoria Regina Thomaz de Oliveira, Carolinne Souza de Amorim, João A. Moraes, Eliezer Jesus Barreiro, Lídia Moreira Lima |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/2/209 |
Similar Items
-
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
by: Changfu Liu, et al.
Published: (2021-02-01) -
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
by: Ryann E. Shor, et al.
Published: (2022-01-01) -
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
by: Cha Len Lee, et al.
Published: (2023-12-01) -
GO-Fe3O4 Nanoparticle Composite for Selective Targeting of Cancer Cells
by: Venkatesha Narayanaswamy, et al.
Published: (2017-03-01) -
The expression of protease-activated receptors in esophageal carcinoma cells: the relationship between changes in gene expression and cell proliferation, apoptosis in vitro and growing ability in vivo
by: Ping Jiang, et al.
Published: (2018-06-01)